The cell therapy industry is rapidly evolving, as described by the recent events below.

1. Stem Cells CAR-T Cord Blood Exosomes Shop
iPSC Market Leaders and their Business Models
Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug
discovery and development, toxicology screening, disease modelling, personalized
medicine, cell-based therapeutics, cultured meat production, and beyond. A fascinatingly
diverse range of business models have been developed by market competitors
from across the life science sector to provide iPSC-derived products, services,
technologies, and therapies.
10 International Scientists Nominated For The $100,000 Stem Cell SpaceShot Grant
Bordeaux, France / August 30th, 2022 – TreeFrog Therapeutics, a biotechnology
company aimed at making safer, more efficient and more affordable cell therapies based
on induced pluripotent stem cells (iPSCs), announced the nomination of 10 international
scientists for the Stem Cell SpaceShot grant. Each nominee was anonymously selected
based on a 1-page research project description. In early October, the 10 nominees will be
interviewed by an international jury of experts in stem cell biology, gene editing and
biophysics, which will determine the winner of the $100,000 Stem Cell SpaceShot Grant.
RoosterBio and AGC Biologics Announce Collaboration to Accelerate
Manufacturing of Cell and Exosome Therapies
SEATTLE, Aug. 16, 2022 — AGC Biologics, a leading global Biopharmaceutical Contract
Development and Manufacturing Organization (CDMO), announced a strategic
partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal
cells (hMSCs), highly engineered media, and bioprocess development services.The
partnership creates an end-to-end solution for the development and production of hMSC
and exosome therapeutics leveraging RoosterBio’s well-established cell and media
products and process development services, coupled with AGC Biologics’ global cell and
gene therapy manufacturing capabilities.
Steakholder Foods Initiates Cultured Pork Development Using a Porcine Cell
Line with Significantly Greater Lifespan and Scalability
Aug 23, 2022, REHOVOT, Israel — Steakholder Foods Ltd. (Nasdaq: STKH) (formerly
MeaTech 3D: $MITC), an international deep-tech food company at the forefront of the
cultured meat industry, has announced that it will begin developing cultured pork products
from a new line of iPS porcine cells. The new stem cell line was derived from sampled
cells that were reprogrammed back into an embryonic-like pluripotent state. This enables
one cell bank to become an unlimited and highly scalable source for developing any type
of muscle or fat cells for cultured meat production.
GIOSTAR is Conducting Research on Stem Cell Therapy, Which May Help
Patients with Osteoarthritis in the Knee
CHICAGO, ILLINIOIS, USA, August 17, 2022 — Global Institute of Stem Cell Therapy and
Research (GIOSTAR), a world leader in stem cell research, is led by Co-Founder and
Chief Scientific Officer Dr. Anand Srivastava. Winner of the 2020 Outstanding
Achievement Award presented by the Society of American Asian Scientists in Cancer
Research (SAASCR), Dr. Srivastava has led the GIOSTAR team in conducting
groundbreaking research on stem cell therapy and other regenerative techniques. This
research is being used to help patients combat a vast array of diseases, such as cancer,
COVID-19, and osteoarthritis in the knees.
Laverock Therapeutics Founded to Develop the Next Generation of
Programmable Cell Therapies
31st August 2022, Stevenage, UK — Laverock Therapeutics Ltd was founded to develop
a unique gene silencing platform for the creation of programmable, allogeneic cell
therapies. Having recently completed a seed funding round, the company's mission is to
utilize Gene Editing induced Gene Silencing (GEiGS®) technology, and its associated
computational platform, to engineer induced pluripotent stem cell (iPSC) derived cell
therapies with improved efficacy, safety, and accessibility.
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat
Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative
therapeutics company StemCyte has received approval from the U.S. FDA for its Phase II
clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell
therapy. PCS is also referred to as Long COVID. StemCyte aims to treat PCS by infusing
umbilical cord blood that is capable of anti-inflammation and tissue repair.
Applied StemCell Announces the Expansion of its cGMP Manufacturing
Facility to Support Cell and Gene Therapy
August 29, 2022, MILPITAS, Calif. — Applied StemCell, Inc. (ASC), a leading cell and
gene therapy CRO/CDMO focused on supporting the research community and
biotech industry for their needs in developing and manufacturing cell and gene
products, announced the expansion of its cGMP facility. ASC has successfully carried out
cell banking and product manufacturing projects in its current cGMP suite and is now set
on building 4 additional cGMP cleanrooms, cryo-storage space, and a process
development and QC/QA space.
CellOrigin Biotech announced strategic global collaboration with Qilu
Pharmaceutical to develop “off-the-shelf” CAR-iMAC cell therapy
Sept. 5, 2022, China, HANGZHOU — CellOrigin Biotech Co., Ltd. has entered a strategic
collaboation with Qilu Pharmaceutical to develop, manufacture and commercialize a
proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-
iMAC) for cancer immnotherapy. This collaboration integrates complementary
technologies and combines industry-leading R&D, manufacture and marketing
capabilities. Both parties will collaborate on new drug development and commercialization,
and will push CAR-iMAC pipelines forward to clinical trials.
Steakholder Foods™ announces Omakase Beef Morsels, a first-of-its-kind,
highly marbled 3D-printed 100% cultured beef cut
Steakholder Foods Ltd. (Nasdaq: STKH) is pleased to introduce Omakase Beef Morsels,
a revolutionary, richly marbled structured meat product developed using a unique 3D-
printing process. Inspired by the marbling standard of Wagyu beef, Omakase Beef
Morsels are an innovative culinary achievement. The product is made up of multiple layers
of muscle and fat tissue, which have been differentiated from bovine stem cells.
CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide
CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and
destroy cancer. In 1987, an Israeli immunologist, Dr. Zelig Eshhar from The Weizmann
Institute of Science, created the world’s first “chimeric antigen receptor” (CAR). Because
CARs are engineered receptors, they do not exist in nature. Today, over one hundred
companies are developing CAR-T technologies from across the globe.
The Pipeline for iPSC-Derived Cell Therapeutics in 2022
The targets for iPSC-derived therapies include any diseases or disorders in which there is
a need to repair or replace dysfunctional tissue. iPSC-derived cells have the potential to
be used as therapies for treating cardiovascular, neurological, and metabolic diseases, as
well as repairing damaged cartilage, spinal, motor neuron, and eye tissues resulting from
genetic defects or injuries. Today, the following companies and organizations are forging
the path toward iPSC-derived cell therapeutics.
Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2022
Induced pluripotent stem cells (iPSCs) are laboratory-made pluripotent stem cells that are
produced using non-controversial adult cells. They are derived from somatic cells through
reprogramming and turning on the expression of specific pluripotency genes. This
reprogramming can be achieved using different techniques with varying efficiencies. iPSC
technology was first discovered in 2006 by Shinya Yamanaka’s lab in Kyoto, Japan. He
and his team introduced four specific genes encoding transcription factors and converted
adult cells into pluripotent stem cells. Dr. James Thomson at the University of Wisconsin-
Madison derived iPSC lines from human somatic cells for the first time in 2007.
How Human iPSCs are Revolutionizing Drug Discovery in 2022
Drug discovery involves high cost and uncertain outcomes. Only a few companies can
take the risk of investing enormous amounts of money into research and testing, only to
see undesirable side effects emerge during the final human clinical trials. In many cases,
companies are spending millions of dollars to fail during clinical testing. Now, some new
medicines are being tested for safety on specialized cells developed from human
pluripotent cell lines. Cell types which are frequently being using within drug discovery
applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the
organs where 80% of drug failures occur.
The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy
What do we know of the safety and efficacy of stem cell therapeutics? Over 50 years have
passed since the discovery of hematopoietic stem cells (bone marrow transplantation to
cure diseases such as leukemia), over 20 years since the discovery of human embryonic
stem cells (hESC), and 16 years since the discovery of induced pluripotent stem cells (iPS
cells). There are now thousands of stem cell trials underway worldwide.
List of Exosome Companies: Tiny Packages, Enormous Potential
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all
eukaryotic fluids and facilitate a range of important cellular functions. In recent years, an
explosion of competitors have been developing exosome therapeutics and diagnostics.
Leaders from across the exosome industry are profiled in this article.
Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires
Lab-grown meat is fast becoming a real alternative to its farm-grown counterpart as
billionaire entrepreneurs and industry heavyweights invest into start-ups from across the
nascent field of “cellular agriculture”. Produced via stem cells derived from cows, pigs,
fish, sheep, or other livestock, the emerging clean meat industry has the potential to
transform the global food market and create a new trillion dollar industry in the process.
Who Discovered Stem Cells? The Answers Revealed
Who discovered stem cells is a question worthy of exploration. While Robert Hooke first
discovered the concept of cells themselves, the discovery of stem cells is usually credited
to Drs. James Till & Ernset McCulloch. For several hundred years, researchers have
known that the human body is comprised of trillions of tiny structures. Known as cells,
these structures can only be seen at a microscopic level. These cells come in hundreds of
variations and serve a diverse range of functions within the human body.
List of Stem Cell Companies Worldwide (2022)
Stem cell companies have been rapidly populating on a global basis. Today, there are
nearly 100 market competitors developing stem cell therapeutics for use in humans. Stem
cells are primitive cells found in all multi-cellular organisms that are characterized by self-
renewal and the capacity to differentiate into mature cell types. Stem cell research has
been going on for over 50 years, because stem cells have a unique ability to divide,
replicate, and differentiate into a diverse range of cell types.
Cord Blood Industry Consolidation Escalates in 2022
The global cord blood industry experienced strong growth from the early 1990’s through
the late 2000’s, during which time more than 450 cord blood banking companies emerged
worldwide. Approximately half of those companies owned their own labs, while the others
were marketing entities or sub-contractors of storage space. Then, the market began
to change course. It entered a period of aggressive consolidation, cutting the global
number of cord blood banks by approximately half. In recent years, the cord blood industry
has witnessed substantial consolidation, particularly within the U.S., Europe, Asia, and
Latin America.
Global Exosome Market - Market Size, Forecasts, Trials, & Trends, 2022
[Market Report]
Exosome technologies have been developing rapidly over the past few years and
substantial growth is expected for the market as they get integrated into the fields of liquid
biopsy, precision medicine and regenerative medicine. To characterize the rapidly
expanding exosome market, BioInformant has released a global strategic report that
explores growing demand for exosome therapeutics, diagnostics, research tools, and
manufacturing technologies. The report reveals trend rate data for exosome patents,
grants, scientific publications, and clinical trials, as well as market size figures with
projections through 2030.
To access other market insights about CAR-T cell therapy, MSCs, iPSCs, cord blood, and
beyond, explore the BioInformant Shop.
*Want to advertise in this newsletter? Contact us at Info@BioInformant.com.